Cboe Global Markets Reports Results for Third Quarter 2025 and Announces Strategic Realignment of Business Portfolio
Third Quarter Highlights* Record Diluted EPS for the Quarter of $2.85, Up 38 percent Record Adjusted Diluted EPS¹ for the Quarter of $2.67, Up 20 percent Record Net Revenue for the Quarter of $605.5 million, Up 14 percent Increases 2025 Organic...
Terumo Interventional Systems Announces Its New OPUSWAVE® Dual Sensor Imaging System and DualView® Imaging Catheter Receive FDA 510(k) Clearance
OPUSWAVE Imaging System combines OFDI and IVUS into a single catheter, providing significant potential to reduce procedural time and costs in treating coronary artery disease DualView imaging catheter offers a 150mm maximum pullback length, a 2.6...
Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/αvβ6 Bispecfic ADC JSKN022
SUZHOU, China, Oct. 24, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed at Sun Yat-sen University Cancer Center in the phase I clinical study (Study ID: JSKN022-101) of...
Renalys Pharma Announces Support for Alport Syndrome Registry Study Organized by Japanese Society for Pediatric Nephrology
TOKYO, Oct. 22, 2025 /PRNewswire/ -- Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys") is pleased to announce the company is providing financial support for the Alport Syndrome Registry Study organized by the Japanese Society for...
Save Now, Travel through March: T'way Air Announces Fall Savings to Korea
Promo Code FLYOCT & Special Coupons for Travel through March 2026 TAIPEI, Oct. 20, 2025 /PRNewswire/ -- T'way Air, Korea's leading low-cost carrier, invites travelers to enjoy special savings through October 31 on Taiwan-Korea bookings for...
Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
AMT-253 is a potential first-in-class MUC18-directed ADC with a proprietary linker-payload design AMT-253 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor based ADCs Promising antitumor activity was observed in heavily...
Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other
AMT-116 is a potential first-in-class CD44v9-directed Topoisomerase I inhibitor-based ADC AMT-116 demonstrated a favorable safety profile, with manageable hematologic and Gastrointestinal toxicities Promising efficacies were observed in patients...
The St. Regis Bar Macao Announces Collaboration with Guerlain for L'Art & La Matière Afternoon Tea
MACAO, Oct. 16, 2025 /PRNewswire/ -- The St. Regis Bar Macao is pleased to present an exclusive collaboration with the Parisian alchemist – Guerlain, a legendary House of high perfumery and high cosmetics, from October 16 to November 15, 2025. The...
Ruko Announces Prime Day Deal on U11MINI 4K Drone - The Lightweight Powerhouse for Summer Adventures
HONG KONG, June 26, 2025 /PRNewswire/ -- Ruko, a brand dedicated to making drones more accessible and enjoyable for everyone, is kicking off a July Promotional Event for its best-selling U11MINI 4K Drone — an ultra-light, feature-packed drone that's...
CJ BIO Announces Participation in IFT 2025, Showcasing Taste Innovation Rooted in Quality and Authenticity
DOWNERS GROVE, Ill., June 25, 2025 /PRNewswire/ -- CJ BIO is proud to announce its fourth consecutive participation in the Institute of Food Technologists (IFT) First Annual Event and Expo, taking place in Chicago this July. Since rejoining the...